Platelet Hyperreactivity Project

Platelet Reactivity Clinical Trial

— PHP  

Official title:

Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00976196
• Other study ID #: 08-104
• Status: Completed
• Phase: N/A
• First received: September 11, 2009
• Last updated: December 1, 2015
• Start date: January 2009
• Est. completion date: January 2010

Study information

• Verified date: December 2015
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Federal Office of Public Health
• Study type: Observational

Clinical Trial Summary

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.

Description:

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.

Main objective:

• to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary objectives:

• to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin

• to determine genetic polymorphisms associated with platelet hyperreactivity

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Documented symptomatic ischemic atherothrombotic disease treated by aspirin.

Exclusion Criteria:

• Known platelet disorder

• Chronic treatment by antiplatelet drugs other than aspirin

• Chronic anticoagulant treatment

• Chronic non steroidal anti-inflammatory drug treatment

• Active cancer

• Treatment with serotonin reuptake inhibitors

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Platelet Reactivity

Locations

Country	Name	City	State
Switzerland	University Hospital Geneva	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
Pierre Fontana

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	genetic polymorphisms associated with platelet hyperreactivity		cross sectional	No
Primary	proteome profile of platelet hyperreactivity	to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients	cross sectional	No
Secondary	platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin		cross sectional	No